MAYO CLINIC

A machine learning algorithm using 12-lead ECGs can detect pulmonary hypertension (PH) with high accuracy, including up to 5 years prior to diagnosis, potentially improving early detection and treatment outcomes.

Genetesis launched CardioFlux Membership, offering regular heart scans at CardioFlux Imaging Institutes to monitor myocardial fitness via CardioFlux Score. The program coincides with the opening of their first institute in Mason, Ohio, with plans for national expansion. The CardioFlux Score, assessable only via Genetesis' CardioFlux MCG device, analyzes 14 biomarkers of heart muscle electrical activity. Memberships are available in three plans, with results accessible via personalized online accounts. Genetesis aims to prevent heart disease through regular heart health monitoring.

Oncology pharmacists are increasingly vital in managing complex cancer therapies, facing challenges like recognition as providers. They run therapeutic clinics, interpret test results, select clinical pathways, and manage patient disease states. Pharmacists also collaborate in tumor boards, write appeal letters, and conduct medication reconciliation for clinical trials. Advocacy efforts aim to elevate their roles in business and policy, with some states recognizing pharmacists as providers. Collaborative practice agreements allow pharmacists to prescribe and manage care, reducing physician workload. However, federal provider status remains unrecognized, limiting reimbursement and resources.

DiMe and CTA launch CHcc project to advance connected health tech, focusing on sustainable hospital-at-home ecosystems and addressing industry fragmentation. Partners include healthcare, tech, patient orgs, and government entities.

Proton beam therapy at Mayo Clinic offers precise radiotherapy for pediatric tumors, reducing radiation to healthy tissues and side effects. Studies show fewer cognitive declines and better survival rates. Mayo Clinic's program uses advanced techniques and collaborates with local care teams for comprehensive pediatric cancer care.

The 21st IMS annual meeting in Rio de Janeiro discussed MRD testing, high-risk disease, CEPHEUS trial, and off-the-shelf CAR T-cell therapy. Topics included MRD testing's impact, defining high-risk myeloma, and the potential of allogeneic CAR T-cell therapy. CEPHEUS trial showed improved MRD negativity and PFS with daratumumab in myeloma treatment.

Mayo Clinic's phase 2 study shows promising results with short-course hypofractionated proton beam therapy for older patients with glioblastoma, improving median overall survival to 13.1 months and quality of life.

Zimmer Biomet received FDA clearance for Osseofit, a stemless shoulder implant designed to match humerus anatomy, preserve bone, and fit ASCs. CEO Ivan Tornos highlighted it as a growth driver. Osseofit uses porous metal, mimicking spongy bone tissue, and is available in a singular instrument tray for workflow efficiency. Zimmer plans to sell it Q1 2025.

Victor Ortega, M.D., Ph.D., discusses how genome-wide technologies enable personal health forecasts, predicting disease risks like heart disease, diabetes, asthma, and cancers through polygenic risk scores. These scores, derived from DNA sequence variants, aim to inform lifestyle choices and enhance screenings, with a focus on precision medicine and health equity.

Syncell closed a $15M Series A funding round, totaling $30M, to expand its Microscoop platform's global commercialization. The platform facilitates high-precision spatial proteomic discovery and protein purification, aiding in research across oncology, neurodegenerative diseases, and drug discovery. Syncell also signed an MOU with Thermo Fisher Scientific and won the 2024 Biotech Breakthrough Award for 'Proteomics Solution of the Year'.